News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,510 Results
Type
Article (39761)
Company Profile (249)
Press Release (659500)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204364)
Career Advice (2007)
Deals (35454)
Drug Delivery (95)
Drug Development (81136)
Employer Resources (172)
FDA (16203)
Job Trends (14866)
News (345529)
Policy (32564)
Tag
Academia (2562)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49474)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16208)
Artificial intelligence (252)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11643)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2253)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (150)
Cell therapy (422)
Cervical cancer (19)
Clinical research (66054)
Collaboration (833)
Compensation (529)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2202)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6372)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86706)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112552)
Executive appointments (724)
FDA (17460)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (746)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (707)
Government (4417)
Grass and pollen (4)
Guidances (65)
Healthcare (18840)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16520)
IRA (40)
Job creations (3633)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7915)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (303)
MASH (67)
Medical device (13410)
Medtech (13415)
Mergers & acquisitions (19479)
Metabolic disorders (683)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1912)
NextGen: Class of 2025 (6520)
Non-profit (4483)
Now hiring (39)
Obesity (362)
Opinion (204)
Ovarian cancer (75)
Pain (88)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (57362)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase I (20580)
Phase II (29090)
Phase III (21673)
Pipeline (1197)
Policy (138)
Postmarket research (2566)
Preclinical (8743)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5911)
Recruiting (65)
Regulatory (22299)
Reports (46)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3579)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (29)
Vaccines (687)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (180)
Last 7 days (871)
Last 30 days (2627)
Last 365 days (32905)
2025 (10670)
2024 (35251)
2023 (40117)
2022 (51227)
2021 (55760)
2020 (54138)
2019 (46581)
2018 (35070)
2017 (32160)
2016 (31528)
2015 (37610)
2014 (31354)
2013 (26388)
2012 (28593)
2011 (29289)
2010 (27360)
Location
Africa (720)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37893)
Australia (6192)
California (6123)
Canada (2012)
China (522)
Colorado (265)
Connecticut (274)
Delaware (147)
Europe (81410)
Florida (910)
Georgia (206)
Idaho (57)
Illinois (534)
India (25)
Indiana (307)
Iowa (11)
Japan (161)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (892)
Massachusetts (4564)
Michigan (220)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1725)
New Mexico (28)
New York (1743)
North Carolina (967)
North Dakota (8)
Northern California (2678)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1374)
Puerto Rico (12)
Rhode Island (33)
South America (1097)
South Carolina (22)
South Dakota (1)
Southern California (2294)
Tennessee (101)
Texas (906)
United States (23087)
Utah (180)
Virginia (144)
Washington D.C. (61)
Washington State (551)
West Virginia (3)
Wisconsin (54)
699,510 Results for "amber ophthalmics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
Amber Therapeutics, a UK-based medical technology company developing a breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence, announces the successful closing of its Series A financing raising a total of $100 million from leading healthcare and technology investors in the US and UK.
June 10, 2024
·
5 min read
Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
Amber Therapeutics (‘Amber’ or the ‘Company’), an innovative medical technology company developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system, announces the presentation of the first data from its AURA-2 (Augmenting Urinary Reflex Activity) first-in-human study evaluating Amber-UI.
February 27, 2024
·
5 min read
Drug Development
Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects
Amber Ophthalmics, Inc. (Amber) , a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient in the AMB-01-006 (NEXPEDE-1) study.
August 18, 2023
·
2 min read
Press Releases
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
April 25, 2025
·
3 min read
Press Releases
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction
January 21, 2025
·
9 min read
Press Releases
Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)
February 14, 2025
·
2 min read
Deals
Amber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform, on which Amber’s closed-loop neuromodulation therapy for mixed urinary incontinence is being developed
Amber Therapeutics announces it has acquired Bioinduction Limited and its Picostim DyNeuMo neuromodulation therapy platform.
September 5, 2023
·
4 min read
Press Releases
LSL PHARMA GROUP ANNOUNCES THE SIGNING OF TWO AGREEMENTS TO MARKET NEW OPHTHALMIC PRODUCTS IN CANADA
April 3, 2025
·
1 min read
Press Releases
Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
April 28, 2025
·
3 min read
Press Releases
Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
March 21, 2025
·
2 min read
1 of 69,951
Next
